Capital Expenditures for Alnylam Pharmaceuticals (ALNY)
According to Alnylam Pharmaceuticals's latest reported financial statements, the company's current capital expenditures (TTM) is $58.70M USD. Capital expenditures (CapEx) are cash outlays for property, plant, and equipment and other long-lived productive assets — reported on the cash flow statement under investing activities. CapEx funds future capacity (factories, data centers, software, machinery), so rising spend can signal investment in growth, while heavy CapEx reduces free cash flow available to shareholders. We display CapEx as a positive amount (the absolute cash outflow); compare with revenue to gauge capital intensity and with total assets for the asset-base context.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Currently viewingCapital ExpendituresSwitch metric
Latest period
$58.70M
YoY change
+71.2%
5Y CAGR
-3.6%
Peak year (2019)
$140.16M
Cumulative capital expenditures
$893.20M
CapEx history chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
CapEx history table for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
| Fiscal year | Period ended | Reported | Capital Expenditures | YoY |
|---|---|---|---|---|
| 2025 | $58.70M | +71.2% | ||
| 2024 | $34.28M | -44.9% | ||
| 2023 | $62.21M | -13.7% | ||
| 2022 | $72.06M | -5.6% | ||
| 2021 | $76.37M | +8.5% | ||
| 2020 | $70.36M | -49.8% | ||
| 2019 | $140.16M | +10.5% | ||
| 2018 | $126.89M | +21.8% | ||
| 2017 | $104.21M | +61.4% | ||
| 2016 | $64.56M | +398.5% | ||
| 2015 | $12.95M | +44.5% | ||
| 2014 | $8.96M | +123.7% | ||
| 2013 | $4.01M | -52.0% | ||
| 2012 | $8.35M | +546.6% | ||
| 2011 | $1.29M | -72.7% | ||
| 2010 | $4.73M | -4.4% | ||
| 2009 | $4.95M | -54.0% | ||
| 2008 | $10.76M | +38.2% | ||
| 2007 | $7.79M | +56.2% | ||
| 2006 | $4.99M | +156.1% | ||
| 2005 | $1.95M | -78.4% | ||
| 2004 | $9.01M | +188.7% | ||
| 2003 | $3.12M | +455.0% | ||
| 2002 | $562,000 | — |
CapEx values are taken from Alnylam Pharmaceuticals's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
Alnylam Pharmaceuticals (ALNY) most recent annual capital expenditures stands at $58.70M (2025) – surged 71.2% year-over-year.
Alnylam Pharmaceuticals capital expenditures compound annual growth for the 2020–2025 (5 years) window is -3.6%, with a net decline across the window.
Between 2019 and 2025, Alnylam Pharmaceuticals capital expenditures plunged 58.1%, falling from $140.16M to $58.70M.
The dataset's maximum capital expenditures sits at $140.16M (2019); the minimum reading of $562,000 dates to 2002.
Among 8 Healthcare peers, Alnylam Pharmaceuticals (ALNY) ranks 9th; the peer median for capital expenditures is $3.87B.
Alnylam Pharmaceuticals Capital Expenditures by Year
Alnylam Pharmaceuticals Capital Expenditures 2025: $58.70M
Alnylam Pharmaceuticals capital expenditures in 2025 was $58.70M, surged 71.2% from 2024.
Alnylam Pharmaceuticals Capital Expenditures 2024: $34.28M
Alnylam Pharmaceuticals capital expenditures in 2024 was $34.28M, plunged 44.9% below 2023.
Alnylam Pharmaceuticals Capital Expenditures 2023: $62.21M
Alnylam Pharmaceuticals capital expenditures in 2023 was $62.21M, declined 13.7% below 2022.
Alnylam Pharmaceuticals Capital Expenditures 2022: $72.06M
Alnylam Pharmaceuticals capital expenditures in 2022 was $72.06M, declined 5.6% below 2021.
Alnylam Pharmaceuticals Capital Expenditures 2021: $76.37M
Alnylam Pharmaceuticals capital expenditures in 2021 was $76.37M.
See more financial history for Alnylam Pharmaceuticals (ALNY).
Sector peers — CapEx
Companies in the same sector as Alnylam Pharmaceuticals, ranked by their latest capital expenditures.
| Company | Capital Expenditures | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $90.11B | Healthcare |
| Eli Lilly and Company (LLY) | $7.84B | Healthcare |
| Johnson & Johnson (JNJ) | $4.83B | Healthcare |
| Merck & Co., Inc. (MRK) | $4.11B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $3.62B | Healthcare |
| AstraZeneca PLC (AZN) | $2.81B | Healthcare |
| Amgen Inc. (AMGN) | $1.86B | Healthcare |
| AbbVie Inc. (ABBV) | $1.21B | Healthcare |
Frequently asked questions
What is Alnylam Pharmaceuticals's capital expenditures?
- Latest reported capital expenditures for Alnylam Pharmaceuticals (ALNY) is $58.70M (period ending December 31, 2025).
How has Alnylam Pharmaceuticals capital expenditures changed year-over-year?
- Alnylam Pharmaceuticals (ALNY) capital expenditures changed +71.2% year-over-year on the latest annual filing.
What is the long-term growth rate of Alnylam Pharmaceuticals capital expenditures?
- Alnylam Pharmaceuticals (ALNY) capital expenditures compound annual growth rate is -3.6% over the most recent 5 years available.
When did Alnylam Pharmaceuticals capital expenditures hit its highest annual value?
- Alnylam Pharmaceuticals capital expenditures reached its highest annual value of $140.16M in 2019.
What was Alnylam Pharmaceuticals capital expenditures in 2024?
- Alnylam Pharmaceuticals (ALNY) capital expenditures in 2024 was $34.28M.
What was Alnylam Pharmaceuticals capital expenditures in 2025?
- Alnylam Pharmaceuticals (ALNY) capital expenditures in 2025 was $58.70M.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
ALNY Overview
Company profile, financial tools, and key metrics
ALNY Revenue Counter
Earns $117.77 every second. See per minute, hour, and day.
ALNY Earnings Counter
Earns $9.95 per second net profit. See per minute, hour, and day.
ALNY Economic Scale
Exceeds Curacao's GDP. Compare with world economies.
ALNY What If Invested
What if you had invested $1,000? See historical returns from any date.
ALNY How It Makes Money
Discover visual breakdown of $3.71B in revenue — where it comes from and where it goes.
ALNY Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
ALNY Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
ALNY Daily Price Character
Explosive · 50.6% historical win rate (green days). Streaks & record days.
ALNY Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.